Hexamethylmelamine-A new drug with activity in solid tumors

Ronald H. Blum, Robert B Livingston, Stephen K. Carter

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Hexamethylmelamine (NSC 13875) is a iriazine that has completed phase I-II trials under the sponsorship of the Division of Cancer Treatment, National Cancer Institute. It was selected for clinical trial based on superior activity against the Walker 256 carcinosarcoma. In the clinical trials reported, the dose schedules used were 4-15 mg/kd/d for 21-90 days. Dose limiting toxicity was gastrointestinal. Also seen were leukopenia, thrombocylopenia, and central nervous system toxicity. The overall response rate in 784 evaluable patients was 17%. Greater than 20% response rates were seen in the following tumor types: small cell (oat) carcinoma of the lung, ovarian adenocarcinoma, lymphoma, and breast cancer. Further controlled clinical trials in certain tumor types are warranted.

Original languageEnglish (US)
Pages (from-to)195-202
Number of pages8
JournalEuropean Journal of Cancer (1965)
Volume9
Issue number3
DOIs
StatePublished - 1973
Externally publishedYes

Fingerprint

Altretamine
Walker Carcinoma 256
Clinical Trials
Pharmaceutical Preparations
Neoplasms
Small Cell Carcinoma
National Cancer Institute (U.S.)
Controlled Clinical Trials
Leukopenia
Lymphoma
Appointments and Schedules
Central Nervous System
Breast Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hexamethylmelamine-A new drug with activity in solid tumors. / Blum, Ronald H.; Livingston, Robert B; Carter, Stephen K.

In: European Journal of Cancer (1965), Vol. 9, No. 3, 1973, p. 195-202.

Research output: Contribution to journalArticle

Blum, Ronald H. ; Livingston, Robert B ; Carter, Stephen K. / Hexamethylmelamine-A new drug with activity in solid tumors. In: European Journal of Cancer (1965). 1973 ; Vol. 9, No. 3. pp. 195-202.
@article{514ca6e0bad0458d99b8974ebc5b7cef,
title = "Hexamethylmelamine-A new drug with activity in solid tumors",
abstract = "Hexamethylmelamine (NSC 13875) is a iriazine that has completed phase I-II trials under the sponsorship of the Division of Cancer Treatment, National Cancer Institute. It was selected for clinical trial based on superior activity against the Walker 256 carcinosarcoma. In the clinical trials reported, the dose schedules used were 4-15 mg/kd/d for 21-90 days. Dose limiting toxicity was gastrointestinal. Also seen were leukopenia, thrombocylopenia, and central nervous system toxicity. The overall response rate in 784 evaluable patients was 17{\%}. Greater than 20{\%} response rates were seen in the following tumor types: small cell (oat) carcinoma of the lung, ovarian adenocarcinoma, lymphoma, and breast cancer. Further controlled clinical trials in certain tumor types are warranted.",
author = "Blum, {Ronald H.} and Livingston, {Robert B} and Carter, {Stephen K.}",
year = "1973",
doi = "10.1016/S0014-2964(73)80019-2",
language = "English (US)",
volume = "9",
pages = "195--202",
journal = "European journal of cancer",
issn = "0014-2964",
publisher = "Pergamon Press Ltd.",
number = "3",

}

TY - JOUR

T1 - Hexamethylmelamine-A new drug with activity in solid tumors

AU - Blum, Ronald H.

AU - Livingston, Robert B

AU - Carter, Stephen K.

PY - 1973

Y1 - 1973

N2 - Hexamethylmelamine (NSC 13875) is a iriazine that has completed phase I-II trials under the sponsorship of the Division of Cancer Treatment, National Cancer Institute. It was selected for clinical trial based on superior activity against the Walker 256 carcinosarcoma. In the clinical trials reported, the dose schedules used were 4-15 mg/kd/d for 21-90 days. Dose limiting toxicity was gastrointestinal. Also seen were leukopenia, thrombocylopenia, and central nervous system toxicity. The overall response rate in 784 evaluable patients was 17%. Greater than 20% response rates were seen in the following tumor types: small cell (oat) carcinoma of the lung, ovarian adenocarcinoma, lymphoma, and breast cancer. Further controlled clinical trials in certain tumor types are warranted.

AB - Hexamethylmelamine (NSC 13875) is a iriazine that has completed phase I-II trials under the sponsorship of the Division of Cancer Treatment, National Cancer Institute. It was selected for clinical trial based on superior activity against the Walker 256 carcinosarcoma. In the clinical trials reported, the dose schedules used were 4-15 mg/kd/d for 21-90 days. Dose limiting toxicity was gastrointestinal. Also seen were leukopenia, thrombocylopenia, and central nervous system toxicity. The overall response rate in 784 evaluable patients was 17%. Greater than 20% response rates were seen in the following tumor types: small cell (oat) carcinoma of the lung, ovarian adenocarcinoma, lymphoma, and breast cancer. Further controlled clinical trials in certain tumor types are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0015599359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0015599359&partnerID=8YFLogxK

U2 - 10.1016/S0014-2964(73)80019-2

DO - 10.1016/S0014-2964(73)80019-2

M3 - Article

VL - 9

SP - 195

EP - 202

JO - European journal of cancer

JF - European journal of cancer

SN - 0014-2964

IS - 3

ER -